Insider Buying: Accelerate Diagnostics Inc (AXDX) Director Acquires 10,000 Shares of Stock
Accelerate Diagnostics Inc (NASDAQ:AXDX) Director John Patience bought 10,000 shares of the business’s stock in a transaction that occurred on Thursday, November 8th. The stock was purchased at an average price of $14.96 per share, with a total value of $149,600.00. Following the completion of the purchase, the director now directly owns 44,670 shares of the company’s stock, valued at approximately $668,263.20. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of NASDAQ AXDX traded up $0.33 during trading hours on Tuesday, reaching $14.82. The stock had a trading volume of 595,600 shares, compared to its average volume of 257,657. The company has a current ratio of 35.26, a quick ratio of 33.54 and a debt-to-equity ratio of 1.52. The firm has a market capitalization of $795.10 million, a price-to-earnings ratio of -12.78 and a beta of 2.49. Accelerate Diagnostics Inc has a twelve month low of $13.25 and a twelve month high of $30.35.
Accelerate Diagnostics (NASDAQ:AXDX) last issued its earnings results on Tuesday, November 6th. The medical research company reported ($0.41) EPS for the quarter, meeting analysts’ consensus estimates of ($0.41). The business had revenue of $1.36 million during the quarter, compared to analyst estimates of $2.89 million. Accelerate Diagnostics had a negative return on equity of 81.76% and a negative net margin of 1,365.75%. On average, research analysts anticipate that Accelerate Diagnostics Inc will post -1.61 earnings per share for the current fiscal year.
A number of research analysts recently commented on AXDX shares. BidaskClub lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, October 5th. Piper Jaffray Companies restated a “buy” rating and issued a $24.00 target price on shares of Accelerate Diagnostics in a research note on Tuesday, August 7th. JPMorgan Chase & Co. lowered Accelerate Diagnostics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $25.00 to $16.00 in a research note on Wednesday, November 7th. Finally, Zacks Investment Research lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Thursday, August 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $20.25.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.
Recommended Story: What is an Initial Public Offering (IPO)?
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.